Konruns(SH:603590) Xin Lang Cai Jing·2025-11-04 02:35Core Insights - 康辰药业's stock price decreased by 5.16% to 46.50 CNY per share, with a trading volume of 75.41 million CNY and a turnover rate of 1.01%, resulting in a total market capitalization of 7.41 billion CNY [1] Company Overview - 康辰药业, established on September 3, 2003, and listed on August 27, 2018, is located in Beijing's Changping District. The company focuses on innovative drug research and development, guided by clinical needs, integrating research, production, and sales [1] - The main revenue sources for 康辰药业 are: 苏灵 (70.77%), 鲑降钙素 (密盖息) (29.15%), and other products (0.09%) [1] Fund Holdings - 中国富达基金 has a significant holding in 康辰药业 through its 富达悦享红利优选混合A fund, which held 156,500 shares, accounting for 4.43% of the fund's net value, making it the seventh-largest holding [2] - The 富达悦享红利优选混合A fund was established on April 30, 2024, with a current size of 36.197 million CNY. Year-to-date returns are 26.36%, ranking 3562 out of 8150 in its category [2] - The fund manager, 聂毅翔, has been in position for 8 years and 96 days, with a total asset size of 281 million CNY, achieving a best return of 135.58% during his tenure [2]